ArticleFrontiers in neuroscience2025
Neuroprotective effect of resveratrol on Epac-1/Rap-1 signaling pathway in ischemic stroke rats.
Article in Frontiers in neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- M2 microglia-derived migrasome-enriched extracellular vesicles restore mitochondrial homeostasis to orchestrate neurovascular unit recovery after ischemic stroke.Journal of nanobiotechnology · 2026Article
- The Bright and Dark Sides of Nitric Oxide in Neurodegenerative Diseases.Journal of personalized medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the neuroprotective effect of resveratrol (Res) and elucidate its underlying mechanism in a rat model of cerebral ischemia-reperfusion injury. Methods: Adult male Sprague-Dawley rats received intraperitoneal Res (40 mg/kg/day) for three consecutive days, followed by transient middle cerebral artery occlusion/reperfusion (MCAO/R). Animals were randomly divided into Sham, MCAO/R, and Res groups. Neurological function was evaluated 24 h after reperfusion. Cerebral infarct volume was assessed by 2,3,5-triphenyltetrazolium chloride (TTC) staining. The serum levels of M1/M2 polarization markers, including the enzymes inducible nitric oxide synthase (iNOS) and arginase-1 (Arg-1), as well as the cytokines interleukin-12 (IL-12) and interleukin-10 (IL-10), were measured by enzyme-linked immunosorbent assay (ELISA). Apoptosis (non-specific neuronal apoptosis) was detected by the terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) staining method. To investigate the underlying mechanism, we focused on the exchange protein directly activated by cAMP-1 (Epac-1) and its downstream effector Ras-related protein 1 (Rap-1), which are known regulators of neuroinflammation. The expression levels of the exchange proteins directly activated by Epac-1 and Rap-1 in ischemic brain tissue were detected using Western blotting. Results: Relative to the Sham group, the MCAO/R group exhibited significantly larger infarct volumes and higher neurological deficit scores, together with increased serum iNOS and IL-12 and decreased IL-10 and Arg-1 (all Conclusion: Res exerts neuroprotective effects against cerebral ischemia-reperfusion injury, potentially by modulating microglial polarization toward the M2 phenotype via the Epac-1/Rap-1 signaling pathway, thereby suppressing inflammation and mitigating neuronal damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.